AACE 2026 Recap: 5 Key Presentations to Know

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to thyroid health and growth hormone deficiencies. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in type 1 diabetes (T1D) took center stage over the 3-day meeting.

With all of the new data and key perspectives being shared throughout the conference, the editorial team at HCPLive has collected 5 of the most impactful headlines to come out of AACE 2026. Catch up on any major data you may have missed during the conference below:

Reemphasizing Nutrition and Diet in Managing Chronic Endocrine Disease, With Jeffrey Mechanick, MD

Jeffrey Mechanick, MD, medical director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital, discusses the importance of employing nutritional goals in managing obesity and preventing additional endocrine diseases. Mechanick highlights the interplay between the metabolic system and the exposome, noting that nutrition is far more than simply diet and exercise – and every aspect has an impact on endocrine health.

Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD

2-year data from the CAHtalyst Adult study have shown substantial and sustained reductions in glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) when treated with crinecerfont. In addition to these positive results, Richard Auchus, MD, PhD, professor of pharmacology and internal medicine at the University of Michigan, discusses the substantial retention observed throughout the open-label extension.

Navigating Iodine Deficiencies and Excesses in Thyroid Health, With Shashank Joshi, MD

Although the risks of iodine deficiency are well-documented, excess iodine also poses substantial risk to the thyroid – and can be caused through unexpected sources, including common micronutrient supplements and iodized salt. To address this, Shashank Joshi, MD, a consultant endocrinologist at Lilavati Hospital and Joshi Clinic, highlights a narrow iodine window that clinicians should target, given the thyroid’s intolerance of extremes in either direction.

Beyond Insulin: Evaluating GLP-1 RAs as Adjunctive Therapy in Type 1 Diabetes, With Viral Shah, MD

Although T1D treatment is largely reliant on insulin therapy, a significant proportion of patients fail to achieve time in range >70%, driven in part by rising rates of obesity. To this end, Viral Shah, MD, a professor of medicine in the division of endocrinology & metabolism and director of Diabetes Clinical Research at the IU Center for Diabetes and Metabolic Diseases at Indiana University, discusses the potential of implementing GLP-1 medications in T1D. Their well-documented efficacy in reducing excess adiposity, coupled with their potentially beneficial effects for cardiovascular health, make them an attractive potential adjunct to existing insulin therapy.

Diabetes Dialogue: Nutrition, Medication, and Treatment in Obesity With Elizabeth Bauer, MD

In a special on-site episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, meet with Elizabeth Bauer, MD, to discuss her “Year in Review” presentation at AACE. AACE’s updated obesity algorithm, emerging obesity pharmacotherapies, and the management of disease and medication side effects take center stage as Bauer covers the full scope of obesity in both the clinical and patient setting.